Dr. Lonial on Data With Belantamab Mafodotin in Multiple Myeloma

Supplements And Featured Publications, Year in Review: Evolving Landscape in Multiple Myeloma, Volume 1, Issue 1

Sagar Lonial, MD, FACP, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses data with belantamab mafodotin in multiple myeloma.

Sagar Lonial, MD, FACP, professor and chair, Department of Hematology and Medical Oncology, Emory University School of Medicine, chief medical officer, Winship Cancer Institute of Emory University, discusses data with belantamab mafodotin in multiple myeloma.

Belantamab mafodotin has shown promising responses in patients with heavily pretreated multiple myeloma as evidenced by data from the phase I DREAMM-1 and phase II DREAMM-2 trials. In the DREAMM-1 trial, the objective response rate (ORR) with the agent was 60% and the median progression-free survival (PFS) was 12 months. Notably, 14 of the 35 patients treated had received ≥5 prior lines of therapy. Additionally, among patients who were refractory to anti-CD38 therapy, the ORR was 31% and the median PFS was 3.4 months.

In the DREAMM-2 trial, investigators evaluated doses of 2.5mg/kg and 3.4mg/kg. Similar responses were seen across both dose levels, says Lonial. Notably, responses were durable. Ocular and hematologic toxicities were well managed with dose adjustments, says Lonial. Now that the safety and activity of the drug has been established, it will be evaluated in combination, concludes Lonial.